首页 /药靶模型 /药靶细胞 /激酶靶点 /EGFR WT (EGF Dependent)/BaF3_Discontinued

EGFR WT (EGF Dependent)/BaF3_Discontinued

CBP73166

询 价
留 言
产品描述
产品数据库

I. Introduction
Cell Line Name: EGFR WT (EGF Dependent)/BaF3
Host Cell: BA/F3
Stability: 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Application: Anti-proliferation assay and PD assay
Freeze Medium: 90% FBS+10% DMSO
Complete Culture Medium: RPMI-1640+10%FBS+100ng/ml EGF
Mycoplasma Status: Negative
 
II. Background

EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section). In ligand-activated cancers, Cetuximab appears to be more effective than tyrosine-kinase inhibitors.

 
III. Representative Data

1.WB of  EGFR WT (EGF Dependent)/BaF3

2. Anti-proliferation assay

Figure 2. Anti-proliferation assay of three reference compounds on the EGFR WT (EGF Dependent)/BaF3 Stable Cell Line.


药靶模型联系方式: 华东销售经理:18240630236 全国销售经理:18066071954
诊断标准品联系方式: 华东销售经理:15000320447 华北销售经理:18131625521 华南销售经理:13484295986 华中&西南销售经理:13871580511 全国销售经理:13484295986

扫二维码

立即提交